Mapping cognitive dysfunction in relapsing multiple sclerosis with mild disability: A cross-sectional study from South India.

Background: Cognitive dysfunction in multiple sclerosis (MS) occurs early. Locally adapted neuropsychological data from India in MS is scarce.

Objectives: We aimed to identify the pattern of cognitive impairment in relapsing MS (RMS) with mild disability using a regionally-adapted MS-specific cognitive battery.

Sacrificial capillary pumps to engineer multiscalar biological forms.

Natural tissues are composed of diverse cells and extracellular materials whose arrangements across several length scales-from subcellular lengths (micrometre) to the organ scale (centimetre)-regulate biological functions. Tissue-fabrication methods have progressed to large constructs, for example, through stereolithography and nozzle-based bioprinting, and subcellular resolution through subtractive photoablation. However, additive bioprinting struggles with sub-nozzle/voxel features and photoablation is restricted to small volumes by prohibitive heat generation and time.

Broad Autism Phenotype Questionnaire - Translation and Validation in a South Indian Language.

Background And Objectives: Broad Autism Phenotype (BAP) refers to specific behaviors or minor deficits in social/communication skills not meeting the diagnostic criteria for autism spectrum disorders (ASDs). The BAP Questionnaire (BAPQ) measures aloof personality (AP), rigid personality (RP), and pragmatic language (PL) deficits of BAP. The study objective is to translate and validate BAPQ into Malayalam, a South Indian language, and to establish new cut-off scores for detecting BAP in the Indian population.

Rituximab in Refractory Myasthenia Gravis - Challenges and Lessons Learnt.

Nearly 10%-15% patients with generalized myasthenia gravis (MG) have refractory disease and are candidates for newer nonconventional immunotherapies. Rituximab has emerged as an attractive option in them. We describe the efficacy and safety of rituximab in 12 patients with refractory MG treated over a period of 4 years in a tertiary care center.